Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...

A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs ...

Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.